Novo's Semaglutide Outperforms Lilly's Trulicity In SUSTAIN 7

Lilly's performance-based plans for Trulicity may be harder to sustain if Novo's competing once-weekly GLP-1 agonist semaglutide is approved in December, following superiority in a head-to-head diabetes study.